A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

INTRODUCTION: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). However, the efficacy of standard subsequent therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, Li, Wei, Gong, Chengcheng, Zheng, Yabin, Ouyang, Quchang, Xie, Ning, Qu, Qing, Ge, Rui, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202336/
https://www.ncbi.nlm.nih.gov/pubmed/34178122
http://dx.doi.org/10.1177/17588359211022890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202336/
https://www.ncbi.nlm.nih.gov/pubmed/34178122
http://dx.doi.org/10.1177/17588359211022890

Ejemplares similares